Juan Francisco Zazueta Pozos

Juan Francisco Zazueta Pozos

Auto-generated profile, based on publicly available information

Juan Francisco Zazueta Pozos

Hematology Department of Hospital General de México, Dr Eduardo Liceaga México City Mexico

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2021 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
PDF file
CMCarlos Martínez-Murillo
Carlos Martínez-Murillo
CPChristian Omar Ramos Peñafiel
Christian Omar Ramos Peñafiel
LBLourdes Basurto
Lourdes Basurto
LBLourdes Balcázar-Hernandez
Lourdes Balcázar-Hernandez
KPKaren Pellon
Karen Pellon
JZJuan Francisco Zazueta
Juan Francisco Zazueta
Aims: To evaluate the frequency of diabetes and admission hyperglycaemia in Mexican COVID‐19 patients, to describe the clinical and biochemical characteristics of patients with admission hyperglycaemia and to determinate the impact of diabetes and admission hyperglycaemia on COVID‐19 severity and mortality.Methods: A multicentric study was performed in 480 hospitalized patients with COVID‐19. Clinical and biochemical characteristics were evaluated in patients with admission hyperglycaemia and compared with non‐hyperglycaemic patients. The effect of diabetes and admission hyperglycaemia on severity and risk of death were evaluated.Results: Age was 50.7 ± 13.6 years; 68.3% were male. Some 48.5% (n = 233) had admission hyperglycaemia; 29% (n = 139) of these patients had pre‐existing diabetes. Patients with admission hyperglycaemia had more requirement of invasive mechanical ventilation (IMV), higher levels of urea, D‐dimer and neutrophil‐lymphocyte ratio (NLR), as well as lower lymphocyte count. An association between admission hyperglycaemia with IMV and D‐dimer with glucose was found. Age ≥50 years (OR 2.09; 95%CI 1.37–3.17), pre‐existing diabetes (OR 2.38; 95%CI 1.59–5.04) and admission hyperglycaemia (OR 8.24; 95%CI 4.74–14.32) were risk factors for mortality.Conclusions: Admission hyperglycaemia is presented in 48.5% of COVID‐19 patients. Diabetes and admission hyperglycaemia are associated with the severity of disease and mortality. This study shows the devastating conjunction of hyperglycaemia and COVID‐19.Clinical trial registration: Clinical characteristics of patients with COVID‐19, DI/20/204/04/41 (Hospital General de Mexico) and NR‐13‐2020 (Hospital Regional de Alta Especialidad Ixtapaluca).

2 April 2026 in Blood Global Hematology
Verified
Journal Article
Open access
JJJosheline Goretti Ramírez Jaramillo
Josheline Goretti Ramírez Jaramillo
ACAlonso Hernández Company
Alonso Hernández Company
GLGilberto Israel Barranco Lampón
Gilberto Israel Barranco Lampón
JPJuan Francisco Zazueta Pozos
Juan Francisco Zazueta Pozos
GJGerardo Santiago Jiménez
Gerardo Santiago Jiménez
CMCarlos Martínez-Murillo
Carlos Martínez-Murillo